ALK Testing Rates Increasing in NSCLC Patients ALK Testing Rates Increasing in NSCLC Patients

Testing for mutations in the ALK gene in patients with non-small-cell lung cancer (NSCLC) who are candidates for targeted therapy nearly doubled from 2011 to 2016, according to a new study in U.S. community practices.Reuters Health Information
Source: Medscape Pathology Headlines - Category: Pathology Tags: Hematology-Oncology News Source Type: news

Related Links:

Expression of prothymosin α in lung cancer is associated with squamous cell carcinoma and smoking. Oncol Lett. 2019 Jun;17(6):5740-5746 Authors: Kuo YH, Shiau AL, Tung CL, Su YC, Li CF, Su BH, Tsao CJ, Wu CL, Feng YH, Wu P Abstract Prothymosin α (ProTα) is a nuclear protein that serves a role in oncogenesis, by promoting proliferation and inhibiting apoptosis in various malignancies. The present study was designed to investigate ProTα expression in resected human non-small cell lung cancer to define the clinicopathological associations of ProTα-positive lung cancer. Immuno...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
In this study, we explored the anti-tumor mechanism and efficacy in vivo of PolyI:C in NSCLC. Our results showed that PolyI:C had the ability to inhibit tumor cell proliferation and promote cell apoptosis by inducing G1 cell cycle block in LL/2 and A549 NSCLC cells. In vivo animal studies also demonstrated that PolyI:C effectively inhibited the tumor growth, suppressed spontaneous metastasis and prolonged the survival time of LL/2 tumor-bearing mice. Moreover, western blotting and immunohistochemistry assays showed that its anti-tumor mechanism was associated with the interference with PI3K/Akt/p53 signaling pathway. Our r...
Source: American Journal of Translational Research - Category: Research Tags: Am J Transl Res Source Type: research
This study aimed to assess the accuracy of computed tomography (CT)...
Source: Cancer Imaging - Category: Radiology Authors: Tags: Research article Source Type: research
Authors: Qin Q, Peng B, Li B Abstract OBJECTIVES: To investigate the impact of EGFR mutations on the efficacy of definitive chemoradiotherapy (CRT) in patients with locally advanced unresectable stage III NSCLC. METHODS: PubMed and EMBASE were searched for eligible studies which compared clinical outcomes according to EGFR status among patients with locally advanced unresectable NSCLC treated with definitive CRT. Efficacy outcomes included objective response rate (ORR), overall disease progression, local regional recurrence (LRR), distant progression (DP), brain metastasis, progression-free survival (PFS) and o...
Source: Expert Review of Anticancer Therapy - Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research
Publication date: August 2019Source: Biomedicine &Pharmacotherapy, Volume 116Author(s): Kai Wu, Jiachen Li, Yu Qi, Chunyang Zhang, Dengyan Zhu, Donglei Liu, Song ZhaoAbstractGefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), has been widely used as a first-line agent in EGFR-mutant non-small cell lung cancer (NSCLC). Nevertheless, the development of chemoresistance ultimately limited the curative effect of anti-cancer drugs. The present study aims to investigate the functions of SNHG14 in gefitinib resistance and gain insight into the underlying molecular mechanisms. In the present stu...
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
ConclusionThe efficacy of osimertinib as second-line treatment or more in octogenarian pretreated patients with EGFR T790M-mutated advanced NSCLC in a real-life setting was similar to that in randomized controlled trials.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research
British Journal of Cancer, Published online: 22 May 2019; doi:10.1038/s41416-019-0464-zMetabolic reprogramming and Notch activity distinguish between non-small cell lung cancer subtypes
Source: British Journal of Cancer - Category: Cancer & Oncology Authors: Source Type: research
Cancers, Vol. 11, Pages 705: LOXL1 Is Regulated by Integrin α11 and Promotes Non-Small Cell Lung Cancer Tumorigenicity Cancers doi: 10.3390/cancers11050705 Authors: Cédric Zeltz Elena Pasko Thomas R. Cox Roya Navab Ming-Sound Tsao Integrin α11, a stromal collagen receptor, promotes tumor growth and metastasis of non-small cell lung cancer (NSCLC) and is associated with the regulation of collagen stiffness in the tumor stroma. We have previously reported that lysyl oxidase like-1 (LOXL1), a matrix cross-linking enzyme, is down-regulated in integrin α11-deficient mice. In the ...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
ConclusionsThere may be pathological and survival differences between cTis/cT1mi tumors and cT1a tumors, but not between cTis tumors and cT1mi tumors.
Source: Surgery Today - Category: Surgery Source Type: research
Publication date: Available online 20 May 2019Source: Journal of Geriatric OncologyAuthor(s): Francesco Cuccia, Gianluca Mortellaro, Rosario Mazzola, Alessandra Donofrio, Vito Valenti, Antonella Tripoli, Domenica Matranga, Antonio Lo Casto, Giuseppe Failla, Giuseppe Di Miceli, Giuseppe FerreraAbstractObjectivesTo investigate whether assessment with two geriatric screening tools shows a correlation with clinical outcomes of patients aged 65 years or more, with early-stage Non-Small Cell Lung Cancer (es-NSCLC) treated with hypofractionated stereotactic radiotherapy.MethodsFrom March 2014 to June 2018 we retrospectively eva...
Source: Journal of Geriatric Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Genetics | Hematology | Lung Cancer | Non-Small Cell Lung Cancer | Pathology | Study